Media coverage about Supernus Pharmaceuticals (NASDAQ:SUPN) has been trending somewhat positive on Monday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.2490379937036 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Supernus Pharmaceuticals Inc (SUPN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Sell or Hold action? Supernus Pharmaceuticals, Inc. (SUPN) – Nasdaq Chronicle (nasdaqchronicle.com)
- Supernus Pharmaceuticals inks deal for new, expanded headquarters – Washington Business Journal (bizjournals.com)
- FY2018 Earnings Estimate for Supernus Pharmaceuticals Inc Issued By Cantor Fitzgerald (SUPN) (americanbankingnews.com)
Supernus Pharmaceuticals (SUPN) opened at $44.85 on Monday. The firm has a market cap of $2,311.43, a price-to-earnings ratio of 42.31 and a beta of 1.07. Supernus Pharmaceuticals has a twelve month low of $26.00 and a twelve month high of $50.04.
A number of equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Berenberg Bank began coverage on shares of Supernus Pharmaceuticals in a report on Thursday, February 1st. They set a “buy” rating and a $66.00 price target on the stock. B. Riley restated a “buy” rating and set a $54.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, January 18th. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $51.36.
In related news, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold a total of 165,750 shares of company stock worth $7,133,973 in the last quarter. Insiders own 6.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/03/12/supernus-pharmaceuticals-supn-receiving-somewhat-favorable-news-coverage-study-finds.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.